Impact of transitioning from HIV clinical trials to routine medical care on clinical outcomes and patient perceptions

References

• Berg , M.B. , Safren , S.A. , Mimiaga , M.J. , Grasso , C. , Boswell , S. and Mayer , K.H. 2005 . Nonadherence to medical appointments is associated with increased plasma HIV RNA and decreased CD4 cell counts in a community-based HIV primary care clinic . AIDS Care , 17 ( 7 ) : 902 – 907 .
   PubMed Web of Science ®Google Scholar
• Braunholtz , D.A. , Edwards , S.J. and Lilford , R.J. 2001 . Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect” . Journal of Clinical Epidemiology , 54 ( 3 ) : 217 – 224 .
   PubMed Web of Science ®Google Scholar
• Daar , E.S. , Tierney , C. , Fischl , M.A. , Sax , P.E. , Mollan , K., , Budhathoki , C. and Collier , A.C. 2011 . Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1: A Randomized Trial . Annals of Internal Medicine , 154 ( 7 ) : 445 – 456 .
   PubMed Web of Science ®Google Scholar
• Davalos , D.M. , Hlaing , W.M. , Kim , S. and de la Rosa , M. 2010 . Recent trends in hospital utilization and mortality for HIV infection: 2000–2005 . Journal of the National Medical Association , 102 ( 12 ) : 1131 – 1138 .
   PubMed Web of Science ®Google Scholar
• Deeks , S.G. , Hecht , F.M. , Swanson , M. , Elbeik , T. , Loftus , R. , Cohen , P.T. and Grant , R. M. 1999 . HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy . AIDS , 13 ( 6 ) : F35 – F43 .
   PubMed Web of Science ®Google Scholar
• DeFreitas , D. 2010 . Race and HIV clinical trial participation . Journal of the National Medical Association , 102 ( 6 ) : 493 – 499 .
   PubMed Web of Science ®Google Scholar
• DHHS . 2011 . Panel on antiretroviral guidelines for adults and adolescents. guidelines for the use of antiretroviralagents in HIV-1-infected adults and adolescents . Retrieved from http://www.aidsinfo.nih.gov/Content Files/AdultandAdolescentGL.pdf
   Google Scholar
• Escobar , I. , Campo , M. , Martin , J. , Fernandez-Shaw , C. , Pulido , F. and Rubio , R. 2003 . Factors affecting patient adherence to highly active antiretroviral therapy . The Annals of Pharmacotherapy , 37 ( 6 ) : 775 – 781 .
   PubMed Web of Science ®Google Scholar
• Fleishman , J.A. , Yehia , B.R. , Moore , R.D. and Gebo , K.A. 2010 . The economic burden of late entry into medical care for patients with HIV infection . Medical Care , 48 ( 12 ) : 1071 – 1079 .
   PubMed Web of Science ®Google Scholar
• Flexner , C. 2007 . HIV drug development: The next 25 years . Nature Reviews of Drug Discovery , 6 ( 12 ) : 959 – 966 .
   PubMed Web of Science ®Google Scholar
• Flexner , C. , Tierney , C. , Gross , R. , Andrade , A. , Lalama , C., , Eshleman , S.H. and Mildvan , D. 2010 . Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: Results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial . Clinical Infectious Diseases , 50 ( 7 ) : 1041 – 1052 .
   PubMed Web of Science ®Google Scholar
• French , B. and Heagerty , P.J. 2008 . Analysis of longitudinal data to evaluate a policy change . Statistics in Medicine , 27 ( 24 ) : 5005 – 5025 .
   PubMed Web of Science ®Google Scholar
• Garcia de Olalla , P. , Knobel , H. , Carmona , A. , Guelar , A. , Lopez-Colomes , J.L. and Cayla , J.A. 2002 . Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients . Journal of Acquired Immune Deficiency Syndrome , 30 ( 1 ) : 105 – 110 .
   PubMed Web of Science ®Google Scholar
• Gifford , A.L. , Bormann , J.E. , Shively , M.J. , Wright , B.C. , Richman , D.D. and Bozzette , S.A. 2000 . Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens . Journal of Acquired Immune Deficiency Syndrome , 23 ( 5 ) : 386 – 395 .
   PubMed Web of Science ®Google Scholar
• Gifford , A.L. , Cunningham , W.E. , Heslin , K.C. , Andersen , R.M. , Nakazono , T., , Lieu , D.K. and Bozzette , S. A. 2002 . Participation in research and access to experimental treatments by HIV-infected patients . New England Journal of Medicine , 346 ( 18 ) : 1373 – 1382 .
   PubMed Web of Science ®Google Scholar
• Giordano , T.P. , Gifford , A.L. , White , A.C. Jr , Suarez-Almazor , M.E. , Rabeneck , L. Hartman , C. 2007 . Retention in care: A challenge to survival with HIV infection . Clinical Infectious Diseases , 44 ( 11 ) : 1493 – 1499 .
   PubMed Web of Science ®Google Scholar
• Grabar , S. , Pradier , C. , Le Corfec , E. , Lancar , R. , Allavena , C., , Bentata , M. and Costagliola , D. 2000 . Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor . AIDS , 14 ( 2 ) : 141 – 149 .
   PubMed Web of Science ®Google Scholar
• Gross , R. , Tierney , C. , Andrade , A. , Lalama , C. , Rosenkranz , S. , Eshleman , S.H. and Mildvan , D. 2009 . Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: A randomized trial . Archives of Internal Medicine , 169 ( 13 ) : 1224 – 1232 .
   PubMed Web of Science ®Google Scholar
• Gulick , R.M. , Mellors , J.W. , Havlir , D. , Eron , J.J. , Gonzalez , C., , McMahon , D. and Richman , D. D. 1998 . Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up . JAMA , 280 ( 1 ) : 35 – 41 .
   PubMed Web of Science ®Google Scholar
• Gulick , R.M. , Ribaudo , H.J. , Shikuma , C.M. , Lalama , C. , Schackman , B.R. , Meyer , W.A. III Kuritzkes , D. R. 2006 . Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial . JAMA 296 7 , 769 – 781 .
   PubMed Web of Science ®Google Scholar
• Gulick , R.M. Ribaudo , H.J. , Shikuma , C.M. , Lustgarten , S. , Squires , K.E. Meyer , W.A. III., 3rd Kuritzkes , D. R. 2004 . Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection . New England Journal of Medicine 350 18 , 1850 – 1861
   PubMed Web of Science ®Google Scholar
• Gwadz , M.V. , Colon , P. , Ritchie , A.S. , Leonard , N.R. , Cleland , C.M., , Riedel , M. and Mildvan , D. 2010 . Increasing and supporting the participation of persons of color living with HIV/AIDS in AIDS clinical trials . Current HIV/AIDS Reports , 7 ( 4 ) : 194 – 200 .
   PubMedGoogle Scholar
• Hogg , R. , Yip , B. , Chan , K. , O′Shaughnessy , M. , & Montaner , J. January 30–February 2 2000 . Nonadherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women (abstract 73) . Paper presented at the program and abstracts of the 7th conference on retroviruses and opportunistic infections . San Francisco , , California : .
   Google Scholar
• Knobel , H. , Carmona , A. , Lopez , J.L. , Gimeno , J.L. , Saballs , P. Gonzalez , A. 1999 . Adherence to very active antiretroviral treatment: Impact of individualized assessment . Enfermedades Infecciosas y Microbiologfa Clinica , 17 ( 2 ) : 78 – 81 .
   PubMedGoogle Scholar
• Lucas , G.M. , Chaisson , R.E. and Moore , R.D. 1999 . Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions . Annals of Internal Medicine , 131 ( 2 ) : 81 – 87 .
   PubMed Web of Science ®Google Scholar
• Mocroft , A. , Gill , M.J. , Davidson , W. and Phillips , A.N. 1998 . Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor . AIDS , 12 ( 16 ) : 2161 – 2167 .
   PubMed Web of Science ®Google Scholar
• Nachega , J.B. , Hislop , M. , Dowdy , D.W. , Chaisson , R.E. , Regensberg , L. and Maartens , G. 2007 . Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes . Annals of Internal Medicine , 146 ( 8 ) : 564 – 573 .
   PubMed Web of Science ®Google Scholar
• Oh , D.L. , Sarafian , F. , Silvestre , A. , Brown , T. , Jacobson , L., , Badri , S. and Detels , R. 2009 . Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among White, Hispanic, and Black men in the MACS Cohort . Journal of Acquired Immune Deficiency Syndrome , 52 ( 2 ) : 290 – 293 .
   PubMed Web of Science ®Google Scholar
• Paredes , R. , Mocroft , A. , Kirk , O. , Lazzarin , A. , Barton , S.E., , van Lunzen , J. and Clotet , B. 2000 . Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study . Archives of Internal Medicine , 160 ( 8 ) : 1123 – 1132 .
   PubMed Web of Science ®Google Scholar
• Paterson , D.L. , Swindells , S. , Mohr , J. , Brester , M. , Vergis , E.N., , Squier , C. and Singh , N. 2000 . Adherence to protease inhibitor therapy and outcomes in patients with HIV infection . Annals of Internal Medicine , 133 ( 1 ) : 21 – 30 .
   PubMed Web of Science ®Google Scholar
• Pence , B.W. , Ostermann , J. , Kumar , V. , Whetten , K. , Thielman , N. and Mugavero , M.J. 2008 . The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy . Journal of Acquired Immune Deficiency Syndrome , 47 ( 2 ) : 194 – 201 .
   PubMed Web of Science ®Google Scholar
• Phillips , A.N. , Staszewski , S. , Weber , R. , Kirk , O. , Francioli , P., , Miller , V. and Ledergerber , B. 2001 . HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load . JAMA , 286 ( 20 ) : 2560 – 2567 .
   PubMed Web of Science ®Google Scholar
• Powderly , W.G. , Saag , M.S. , Chapman , S. , Yu , G. , Quart , B. and Clendeninn , N.J. 1999 . Predictors of optimal virological response to potent antiretroviral therapy . AIDS , 13 ( 14 ) : 1873 – 1880 .
   PubMed Web of Science ®Google Scholar
• Riddler , S.A. , Haubrich , R. , DiRienzo , A.G. , Peeples , L. , Powderly , W.G., , Klingman , K.L. and Mellors , J. W. 2008 . Class-sparing regimens for initial treatment of HIV-1 infection . New England Journal of Medicine , 358 ( 20 ) : 2095 – 2106 .
   PubMed Web of Science ®Google Scholar
• Robbins , G.K. , De Gruttola , V. , Shafer , R.W. , Smeaton , L.M. , Snyder , S.W., , Pettinelli , C. and Hirsch , M. S. 2003 . Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection . New England Journal of Medicine , 349 ( 24 ) : 2293 – 2303 .
   PubMed Web of Science ®Google Scholar
• Routman , J.S. , Willig , J.H. , Westfall , A.O. , Abroms , S.R. , Varshney , M. , Adusumilli , S. and Mugavero , M. J . 2010 . Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care . Clinical Infectious Diseases , 50 ( 4 ) : 574 – 584 .
   PubMed Web of Science ®Google Scholar
• Saag , M. , Krowles , M. , Chang , Y. , Chapman , S. , Clendeninn , N.J. , & Viracept Cooperative Study Group . 1997 . Durable effect of Viracept (nelfinavir mesylate, NFV) in triple combination therapy [abstract I-101] . Paper presented at the programs and abstracts of the 37th international conference on antimicrobial agents and chemotherapy. . San Diego , , California : .
   Google Scholar
• Sax , P.E. , Tierney , C. , Collier , A.C. , Fischl , M.A. , Mollan , K., , Peeples , L. and Daar , E. S. 2009 . Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy . New England Journal of Medicine , 361 ( 23 ) : 2230 – 2240 .
   PubMed Web of Science ®Google Scholar
• Shafer , R.W. , Smeaton , L.M. , Robbins , G.K. , De Gruttola , V. , Snyder , S.W., , D'Aquila , R.T. and Merigan , T. C. 2003 . Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection . New England Journal of Medicine , 349 ( 24 ) : 2304 – 2315 .
   PubMed Web of Science ®Google Scholar
• Weintrob , A.C. , Grandits , G.A. , Agan , B.K. , Ganesan , A. , Landrum , M.L., , Crum-Cianflone , N.F. and Marconi , V. C. 2009 . Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care . Journal of Acquired Immune Deficiency Syndrome , 52 ( 5 ) : 574 – 580 .
   PubMed Web of Science ®Google Scholar
• Yehia , B.R. , Fleishman , J.A. , Gebo , K.A. , Agwu , A.A. 2011 . Disparities in HAART Receipt for HIV-infected Adults in Care . Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections .
   Google Scholar
• Yehia , B.R. , Fleishman , J.A. , Hicks , P.L. , Ridore , M. , Moore , R.D. and Gebo , K.A. 2010 . Inpatient health services utilization among HIV-infected adult patients in care 2002–2007 . Journal of Acquired Immune Deficiency Syndrome , 53 ( 3 ) : 397 – 404 .
   PubMed Web of Science ®Google Scholar